Bussetty Arvind, Shen Jing, Benias Petros C, Ma Michael, Stewart Molly, Trindade Arvind J
Department of Medicine, Rutgers University School of Medicine, New Brunswick, New Jersey.
Division of Gastroenterology, Rutgers University School of Medicine, New Brunswick, New Jersey.
JAMA Netw Open. 2025 Apr 1;8(4):e254682. doi: 10.1001/jamanetworkopen.2025.4682.
Pancreas cancer is the seventh leading cause of cancer death and colorectal cancer is the second leading cause of cancer death worldwide, with increasing incidence for both, particularly in younger age cohorts.
To report updated incidence trends for pancreas and colorectal adenocarcinomas in the US, with the specific intent of examining the annual percentage changes (APCs) in younger age groups.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results database to examine incidence trends from 2000 to 2021. Individuals with pancreatic and colorectal adenocarcinoma were included. Data through 2021 were released on April 17, 2024. Data analysis occurred from December 4, 2024, to February 1, 2025.
Yearly incidence rates were obtained for pancreatic and colorectal adenocarcinoma. Temporal trends of pancreas adenocarcinoma incidence rates by covariates were measured by APC and 95% CIs.
From 2000 to 2021, 275 273 cases of pancreas adenocarcinoma were identified (142 633 male patients [51.8%]; 239 840 patients [87.1%] aged ≥55 years). The APC for pancreatic adenocarcinoma was 4.35 (95% CI, 2.03 to 6.73) in the group aged 15 to 34 years, which was statistically significantly higher than the APCs of 1.74 (95% CI, 1.59 to 1.89) (P = .007) for the group aged 55 years and older and 1.54 (95% CI, 1.18 to 1.90) (P = .004) for the group aged 35 to 54 years. A total of 1 215 200 cases of colorectal cancer were identified (641 776 male patients [52.8%]; 976 716 patients [80.4%] aged ≥55 years). The APC for colorectal adenocarcinoma was -3.31 (95% CI, -3.54 to -3.08) for the group aged 55 years and older, which was statistically significantly lower than the APCs of 1.75 (95% CI, 1.08 to 2.42) (P = .001) for the group aged 15 to 34 years and 0.78 (95% CI, 0.51 to 1.06) (P = .002) for the group aged 35 to 54 years.
The findings of this cohort study suggest that the incidence of pancreatic adenocarcinoma has increased among all age groups, whereas that of colorectal adenocarcinoma has increased among younger age groups. Clinicians should be aware of this trend when evaluating younger patients with relevant symptoms.
胰腺癌是全球癌症死亡的第七大主要原因，结直肠癌是第二大主要原因，两者发病率均呈上升趋势，尤其是在较年轻的人群中。
报告美国胰腺癌和结直肠腺癌的最新发病率趋势，特别关注较年轻年龄组的年百分比变化（APC）。
设计、设置和参与者：这项回顾性队列研究使用了监测、流行病学和最终结果数据库的数据，以研究2000年至2021年的发病率趋势。纳入了患有胰腺和结直肠腺癌的个体。2021年的数据于2024年4月17日发布。数据分析于2024年12月4日至2025年2月1日进行。
获取胰腺癌和结直肠腺癌的年发病率。通过APC和95%置信区间测量胰腺腺癌发病率按协变量的时间趋势。
2000年至2021年，共识别出275273例胰腺腺癌病例（142633例男性患者[51.8%]；239840例患者[87.1%]年龄≥55岁）。15至34岁年龄组胰腺腺癌的APC为4.35（95%置信区间，2.03至6.73），在统计学上显著高于55岁及以上年龄组的APC 1.74（95%置信区间，1.59至1.89）（P = 0.007）和35至54岁年龄组的APC 1.54（95%置信区间，1.18至1.90）（P = 0.004）。共识别出1215200例结直肠癌病例（641776例男性患者[52.8%]；976716例患者[80.4%]年龄≥55岁）。55岁及以上年龄组结直肠腺癌的APC为-3.31（95%置信区间，-3.54至-3.08），在统计学上显著低于15至34岁年龄组的APC 1.75（95%置信区间，1.08至2.42）（P = 0.001）和35至54岁年龄组的APC 0.78（95%置信区间，0.51至1.06）（P = 0.002）。
这项队列研究的结果表明，胰腺癌在所有年龄组中的发病率均有所上升，而结直肠腺癌在较年轻年龄组中的发病率有所上升。临床医生在评估有相关症状的年轻患者时应注意这一趋势。
